Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2024-03-26 Earnings Release
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Earnings Release Classification · 95% confidence The document is explicitly titled 'FORM 6-K' and is filed by a 'FOREIGN PRIVATE ISSUER'. Form 6-K is a general report used by foreign private issuers to report material information not required to be reported on a schedule 13D or 13G or Form 20-F. The content of this specific 6-K is a press release announcing the company's '2023 Financial Results and Recent Corporate and Portfolio Updates'. This structure—a formal SEC filing (6-K) containing an earnings press release—is most closely aligned with an Earnings Release (ER) or, given the comprehensive nature of the financial details provided (full year results, balance sheet items, P&L), it could also be considered an Interim/Quarterly Report (IR) if it were a quarterly filing, but since it covers the full year and is filed on Form 6-K, it functions as the primary disclosure of annual results outside of the 20-F. However, the document *also* explicitly mentions the filing of the Form 20-F and provides the full financial details, which leans towards a comprehensive report. Since the primary content is the detailed annual financial results announcement, and it is not a 10-K, the best fit among the provided options for a comprehensive annual financial disclosure outside of the 10-K/20-F structure is often the Earnings Release (ER) category, as it contains the core financial highlights and management discussion, even though it's more detailed than a typical ER. Given the comprehensive nature of the financial results (including balance sheet figures and detailed expense breakdowns for the full year), it strongly resembles the content of an Annual Report, but it is filed on Form 6-K, not Form 10-K. In the context of US filings, a 6-K containing annual results is often categorized as an Earnings Release (ER) or a general Regulatory Filing (RNS) if the ER category is too narrow. Since it contains detailed financial results and management discussion, ER is the strongest fit for the *content*, even though the wrapper is 6-K. If the document were purely the announcement of the 20-F filing, it would be RPA. Since it contains the results themselves, ER is appropriate. FY 2023
2024-03-26 English
Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Report Publication Announcement Classification · 98% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' filed under Israeli Securities Authority regulations. It mentions 'BioLineRx Reports 2023 Financial Results' and attaches a PDF file named 'Form_6-K_26-Mar-24_isa.pdf'. A Form 6-K is typically used by foreign private issuers to report material information not required to be reported under the regular SEC filing system, often accompanying earnings releases or interim updates. Since this document announces the release of the 2023 Financial Results and is short (1930 chars) and points to an attached report, it fits the definition of a Report Publication Announcement (RPA) rather than the full Interim Report (IR) or Annual Report (10-K) itself. The content strongly suggests an earnings announcement wrapper.
2024-03-26 English
6-K
Regulatory Filings
2024-03-26 English
6-K
Regulatory Filings
2024-03-04 English
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
Regulatory Filings Classification · 98% confidence The document is explicitly identified as a "FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934" for the month of March 2024. Form 6-K is a periodic report required by the SEC for foreign private issuers, often used to file material information that is otherwise required to be disclosed in the home country or made public there. The content itself is a press release announcing the allowance of a U.S. Patent covering manufacturing methods for Motixafortide (BL-8040). While the content relates to intellectual property and product development, the filing wrapper is the key identifier. Since Form 6-K is a general periodic/current report for foreign issuers and doesn't map directly to the specific categories like 10-K (Annual Report) or ER (Earnings Release), it falls best under the general regulatory filing category, which is RNS (Regulatory Filings), as it is a mandatory SEC filing that doesn't fit the more specific definitions provided (like AGM-R, CT, DIRS, etc.). Although it contains information that could relate to IP, the primary document type is the SEC filing itself.
2024-03-04 English
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
Report Publication Announcement Classification · 98% confidence The document is a short filing (2144 chars) from BioLineRx, dated 04/03/2024, reporting an update on intellectual property (Notice of Allowance for U.S. Patent). It explicitly states, "Attached hereto is a report on... *FORM_6-K_4-Mar-2024_isa.pdf*". This structure—a brief announcement pointing to an attached, more detailed document (a Form 6-K, which is a general report for foreign issuers)—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. It is announcing the publication of a report rather than being the full report itself. While it could potentially be classified as RNS (Regulatory Filings), RPA is more specific for announcements about report publication.
2024-03-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.